|  |
| Astellas' Hostile Takeover Turns Even More Hostile
| The Japan-based company filed a lawsuit against OSI Pharmaceuticals for rejecting its tender offer, but will this strategy work? | | | Novartis Bids Big on Alcon
| | It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon. | | | Glaxo Vies for a Second Act in HIV
| | A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. | | | J&J Slims Down Elan Offer sans Tysabri
| | Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move. | | | GSK Signs $120M Deal to Market DMab Overseas
| | Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved. | | | GSK Teams with Shenzhen Neptunus for Chinese Vaccines
| | GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people. | | | GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
| | GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body. | | | Pfizer and Glaxo Join Forces in HIV Venture
| | The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market. | | | GSK Grabs Derma Firm for $2.9 Billion
| | Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line. | |  MORE ARTICLES
|
| |
| Bolder is Better
| | As oncology grows, its advertising is growing up—leaving behind the mechanistic images and scientific themes of past campaigns | | | MORE ARTICLES
|
| |
| India: An Emerging Knowledge Superpower
| | "India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making. | | | MORE ARTICLES
|
| |
| Web Infinity - And Beyond!
| | Three ad agencies came up with two similarly designed ways of keeping track of online healthcare conversation, harnessing the power of social media sites like Twitter and Digg. | | | MicroMass
| | The faces and names behind the year's best pharmaceutical advertising. | | | JWT
| | The faces and names behind the year's best pharmaceutical advertising. | | | DDB New York
| | The faces and names behind the year's best pharmaceutical advertising. | | | DraftFCB
| | The faces and names behind the year's best pharmaceutical advertising. | | | Echo Torre Lazur
| | The faces and names behind the year's best pharmaceutical advertising. | | | Cadient Interactive
| | The faces and names behind the year's best pharmaceutical advertising. | | | EuroRSCG Tonic
| | The faces and names behind the year's best pharmaceutical advertising. | | | Palio
| | The faces and names behind the year's best pharmaceutical advertising. | | | MORE ARTICLES
|
| |
| Perception is Reality
| | In this day and age of regulations and austerity, upscale venues are no longer able to put on the ritz | | | Information, Education, and Talk Trump Free Pens
| | Exhibit marketers can breath a sigh of relief to find out that the new code is having little impact on attendance | | | The Shrinking Pool
| | Public scrutiny, regulations, and pharma's image are taking a toll on the availability of KOLs | | | Two Views From Inside The Exhibition Booth
| | No longer just a meet-and-greet venue, the exhibition booth has become an effective selling channel | | | Physician Meetings: A Bright Future
| | The good news is that as the industry changes its sales force model, the need for meetings will increase | | | Pharma Meetings
| | Neither Washington nor the public has any patience for executives playing golf at fancy resorts. It doesn't matter if they are there attending a conference, or that important business is often conducted on the green, or that the Battle of Waterloo was won on the playing fields of Eton. | | | So, You Want To Be A Preferred Vendor
| | Five keys to being on Pharma's preferred vendors' short list | | | Crisis Spurs Coming of Age of Global Meeting Planning
| | The more mature a Global Strategic Meetings Management Program is, the better the meetings, and the more significant the cost savings | | | Working Well With Others
| | More than ever, pharma companies are relying on a stable of preferred vendors to plan and execute meetings and events. Recently, meeting planner Sue Potton was asked, among other things, about what both parties need to know to forge a successful partnership. | | | MORE ARTICLES
|
| |
| Pharma Trials Heading South
| | Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials. | | | No Such Thing as Free Drugs?
| | New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.? | | | Wrangling Over Research Results
| | Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion. | | | A Review of Tafas v. Doll | | Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules. | | | New Study Reveals Distribution Trends in Drug Sampling
| | Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees. | | | Data Mining Companies Score Legal Win in Maine
| | IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms. | | | BioMS Medical Signs $500 Million Agreement with Lilly
| | Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. | |
| | Preemption Gets Boost from Bush
| | State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer? | | | BMS Cuts Bloated Manufacturing Arm to Bolster R&D
| | Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing. | | | MORE ARTICLES
|
| |
| GSK Chooses MediaCom for a Billion-Dollar Planner Contract
| | GlaxoSmithKline locks up MediaCom as its only ad-buying/planning provider. The agency will handle GSK's massive ad spend, which last year hovered around $1.1 billion. | | | Vertex Pharmaceuticals Brings Transparency Online
| | Drug manufacturer shakes things up with new Web site that functions as an open book into the world of Vertex Pharmaceuticals. The company hopes that its transparent approach to design will be a lesson to pharma companies still fearful of online media. | | | Arkansas Attorney General Takes J&J to Task
| | The State of Arkansas filed suit against Risperdal manufacturer Johnson & Johnson, claiming promotion of the drug for nonmedical uses has led to increased prescriptions being written and bigger payouts by Medicaid. | | | In Defense of Peer Review: Waxman Opponents Argue for Distribution of Off-Label Info
| | Peer-review advocates speak out against Congressman Waxman?s stance on a new policy that would allow pharma to distribute unbiased journal articles to doctors without prior approval. | | | Doc-Driven Search Site Lists Top Search Terms
| | A physician-oriented search engine reveals its most-searched terms. Among the winners: breast and lung cancer, cortisol, and HbA1c/glycated hemoglobin. Nowhere to be seen: pharmaceutical products. | | | Discovery Health Documentary Spotlights Diabetes and Offers a CME Credit
| | A new pharma-sponsored documentary chronicles one doctor?s adventure around the world as she searches for stories about living with diabetes. The program, sponsored by Novo Nordisk, enlightens viewers and offers physicians a chance to earn one AMA-approved CME credit. | | | GSK Told to Update Avandia Warnings
| | Faced with contradictory data about the safety of the diabetes treatment, FDA asks for a black-box warning and additional trials. But how much damage will the black box do? | | | Lilly's New Blood Thinner No Blockbuster
| | Safety Risks, Generic Threat Scale Down Big Hopes | | | Stormy Forecast for Pharma in 2008
| | Bright Spots Are Emerging Markets, Specialty Drugs, Says IMS Health | | | MORE ARTICLES
|
| |
| |
| Rx Abandonment Rate Continues to Rise
| | The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens. | | | Wyeth Purchase Boosts Pfizer Profits
| | Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast. | | | Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics
| | Today?s rapidly changing commercial and regulatory landscape demands better information faster than ever before. Pharmaceutical companies need to adapt quickly to effectively market and sell products while reducing the cost of sales. The Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics is a prebuilt, high-performance solution designed to address today?s information needs, with the extensibility and scalability to meet tomorrow?s. | | | Tearing Up the Rule Book
| | Sales compensation practices are due for an overhaul in 2010. | | | AHF Puts Kibosh on Merck Rep Visits
| | AIDS treatment provider says the high price of Merck's Isentress is limiting patient access. Merck says banning its reps is what limits access. While Mom and Dad are fighting, does the patient lose out? | | | The Big Reset
| | Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer? | | | | Antidepressants Might Not Be A Sure Shot
| | A new JAMA study reveals that antidepressants might not have as strong an effect on people with less severe cases of depression. How this will affect the pharma industry, which once made heaps of cash with drugs like Prozac, remains to be seen. | | | Layoffs and Job Cuts Brewing at Sanofi-Aventis
| | With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions. | | | The Zen Approach to Transforming the Traditional Sales Model
| | Don't throw the sales force out with the bathwater. Accomplish more with fewer reps, less money and little effort. Impossible? Read on... | | | MORE ARTICLES
|
| |
| Emerging Markets to Account for Half of Market Growth by 2013
| | A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity? | | | The New Merck's Move on Emerging Markets
| | Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world? | | | The Race Is On
| | Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect? | | | Sixth Annual Press Audit
| | Pricing, promotion, and the unfinished story of healthcare reform dominated the news last year. | | | Stay Ahead of the Technology Curve
| | In a digital world, vast quantities of data at hand are a powerful asset. Managing that information is key to seizing competitive advantage. | | | Merck: Mergers and Layoffs and Pipelines, Oh My!
| | The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts. | | | Ernst & Young Puts the Spotlight on Pharma 3.0
| | The blockbuster model has been dead for a while, but pharma is just now researching new ways to reach patients. Pharm Exec interviews Carolyn Luce at Ernst & Young to learn more about the new era of pharma outreach and marketing. | | | Wyeth Purchase Boosts Pfizer Profits
| | Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast. | | | Tearing Up the Rule Book
| | Sales compensation practices are due for an overhaul in 2010. | | | MORE ARTICLES
|
| |
| Proven Reliability in Temperature Controlled Shipping
| | American Airlines Cargo has implemented a high-visibility, multi-layered system for temperature-controlled shipping that has gained accreditation in 60 cities in 24 countries worldwide. American?s ExpediteTC solution delivers the kind of specialized air cargo expertise demanded by pharmaceutical customers and their freight forwarders. | | | Business Intelligence Case study: Abbott Laboratories
| | Abbott Laboratories tapped Kalido?s model-driven data warehousing infrastructure to revamp?and revive?an overworked BI system. Executives can view accurate, timely data in each of several different contexts?historical, current, or future. The new system also gives Abbott?s sales and marketing executives better insight into how efficiently the company is allocating its sales and marketing investments, particularly in emerging markets. | | | Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics
| | Today?s rapidly changing commercial and regulatory landscape demands better information faster than ever before. Pharmaceutical companies need to adapt quickly to effectively market and sell products while reducing the cost of sales. The Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics is a prebuilt, high-performance solution designed to address today?s information needs, with the extensibility and scalability to meet tomorrow?s. | | | Data Governance: Business Data You Can Believe In
| | Bad data ? and a lack of good data management practices ? can cost your business millions of dollars every year. You have to treat your data like every other valuable asset in your business: You must protect it, nurture it and ensure that, like any asset, it?s in the best condition possible. | | | Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast
| | | | Cut the Cord and Take to the Cloud
| | One feature that should be considered when looking for a new software-as-a-service (SaaS) system is multi-tenancy, which is a chief characteristic of a mature cloud computing application. Here?s what to look for. | | | Calculating Risk
| | A risk-based approach to records and information management can be an integral part of the effort to reduce costs stemming from litigation. | | | Bank on IT
| | Tough economic tmes call for a bold approach to evolving information technology solutions. | | | Search for: Meaning
| | Here's how to search for meaning through unstructured data. | | | MORE ARTICLES
|
|
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?